A Molecular Switch To Control Tnfr2 During Atherogenesis In Vivo

Yiting Jia,Wei Kong

DOI: https://doi.org/10.1161/ATVBAHA.116.308840

2017-01-01

Arteriosclerosis Thrombosis and Vascular Biology

Abstract: disintegrin and metalloproteinase 17 (ADAM17) is a major sheddase of membrane-anchored cytokines, cell adhesion molecules, receptors, ligands, and enzymes, such as tumor necrosis factor-α (TNF-α), transforming growth factor-α, TNF-α receptor 1 (TNFR1), TNF-α receptor 2 (TNFR2), and interleukin-6 receptor, L-selectin, Notch, and angiotensin-converting enzyme type 2, in which way could modulate a variety of signaling transduction and affect cell behavior.1–4 The consequence of shedding events mainly depends on the type of substrate shed, the generation of soluble receptor agonists or antagonists, and the cell type and specific tissues affected during various disease states.Figure. A , Protective role of a disintegrin and metalloproteinase 17 (ADAM17) in atherosclerosis. B , deficiency reduces shedding of tumor necrosis factor receptor 2 (TNFR2) and tumor necrosis factor-α (TNF-α), thereby promotes membrane TNFR2 accumulation and persistent TNFR2 signaling activation, and enhances the downstream antiapoptosis and proproliferation effects in macrophages and vascular smooth muscle cells. BMX indicates bone marrow tyrosine kinase in chromosome X; sTNF-α, soluble TNF-α; and sTNFR2, soluble TNFR2.See accompanying article on page 247 ADAM17 was first identified to process membrane-bound TNF-α precursor to a soluble form. In addition, TNF receptors, …